ArticleAmerican journal of translational research2024
Integration of bulk RNA-seq and single-cell RNA-seq constructs: a cancer-associated fibroblasts-related signature to predict prognosis and therapeutic response in clear cell renal cell carcinoma.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inter- and intra-quartile comparison of multi-tracer PET/CT and liquid biopsy molecular markers in cancer: a futuristic perspective on evolving a "stepped care" model for individualized precision theranostics through AI/ML.European journal of nuclear medicine and molecular imaging · 2026Article
- Integrative Multiomics and Single-Cell Analyses Identify FKBP10 as a Predictor of Radiotherapy Outcome in Colorectal Cancer.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is a common and aggressive renal cancer with high mortality when metastasized. Cancer-associated fibroblasts (CAFs) are pivotal in ccRCC evolution; however, their significance in forecasting prognosis and guiding therapy is undetermined.
methodWe used Weighted Correlation Network Analysis to identify modules correlated with CAFs in bulk RNA-seq data. We also screened fibroblast marker genes in single-cell RNA-seq data and upregulated genes in TCGA tumor samples and defined genes identified in all three analyses as CAFs-related genes (CRGs). We extracted a CRG signature using Least Absolute Shrinkage and Selection Operator analysis and investigated its biological mechanisms by combining Gene Set Enrichment Analysis and the AUCell algorithm. The Tumor Immune Dysfunction and Exclusion algorithm and the IMvigor 210 dataset were employed to assess the signature's capability to predict immunotherapeutic responses. Additionally, we analyzed the relationship between the signature and the IC
resultsThe CRG signature was anchored on six genes: CERCAM, TMEM132A, TIMP1, P4HA3, FKBP10, and CEBPB. Kaplan-Meier analysis indicated that patients with high expression of the signature experienced poorer survival than those with low expression. Furthermore, immunotherapy was more effective in patients with low signature expression. In vitro assays revealed CERCAM silencing led to a substantial reduction in the proliferative and migratory capacities of ccRCC cell lines.
conclusionOur CRG signature holds promise in forecasting prognosis and guiding personalized treatment for patients with ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.